(S (NP (ADJP (JJ Complex) (CC or) (JJ co-existing)) (NNS diseases)) (VP (VBP are) (ADVP (RB commonly)) (VP (VBN treated) (S (VP (VBG using) (NP (NP (NN drug) (NNS combinations)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (JJ adverse) (NN side) (NNS effects)))))))))))))) (. .))
(S (S (NP (NP (DT The) (NN detection)) (PP (IN of) (NP (JJ polypharmacy) (NN side) (NNS effects)))) (VP (VBZ is) (ADVP (RB usually)) (VP (VBN done) (PP (IN in) (NP (NNP Phase) (NNP IV) (JJ clinical) (NNS trials)))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP are) (ADVP (RB still)) (NP (NP (JJ plenty)) (SBAR (WHNP (WDT which)) (S (VP (VBP remain) (ADJP (JJ undiscovered)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNS drugs)) (VP (VBP are) (VP (VBN put) (PP (IN on) (NP (DT the) (NN market))))))))))))) (. .))
(S (S (NP (JJ Such) (NNS accidents)) (VP (VBP have) (VP (VBN been) (VP (VBG affecting) (NP (NP (NP (DT an) (VBG increasing) (NN proportion)) (PP (IN of) (NP (DT the) (NN population)))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (PP (IN in) (NP (DT the) (NNP US))) (ADVP (RB now)) (-RRB- -RRB-))))))) (CC and) (S (NP (NP (PRP it))) (VP (VBZ is) (ADVP (RB thus)) (PP (IN of) (NP (JJ high) (NN interest))) (S (VP (TO to) (VP (VB be) (ADJP (JJ able) (S (VP (TO to) (VP (VB predict) (NP (DT the) (JJ potential) (NN side) (NNS effects)) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (ADJP (JJ possible))))))))))))) (. .))
(S (NP (NP (JJ Systematic) (JJ combinatorial) (NN screening)) (PP (IN of) (NP (NP (JJ possible) (JJ drug-drug) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NNP DDI)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (VBG challenging) (CC and) (JJ expensive))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ recent) (JJ significant) (NNS increases)) (PP (IN in) (NP (NNS data) (NN availability))) (PP (IN from) (NP (JJ pharmaceutical) (NN research) (CC and) (NN development) (NNS efforts)))) (VP (VBP offer) (NP (NP (DT a) (JJ novel) (NN paradigm)) (PP (IN for) (S (VP (VBG recovering) (NP (NP (JJ relevant) (NNS insights)) (PP (IN for) (NP (NNP DDI) (NN prediction))))))))) (. .))
(S (ADVP (RB Accordingly)) (, ,) (NP (JJ several) (JJ recent) (NNS approaches)) (VP (VBP focus) (PP (IN on) (S (VP (VP (VBG curating) (NP (NP (JJ massive) (NNP DDI) (NNS datasets)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NNS millions)) (PP (IN of) (NP (NNS examples))))) (-RRB- -RRB-)))) (CC and) (VP (VBG training) (NP (NN machine) (VBG learning) (NNS models)) (PP (IN on) (NP (PRP them)))))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ neural) (NN network) (NN architecture)) (ADJP (JJ able) (S (VP (TO to) (VP (VB set) (NP (NP (JJ state-of-the-art) (NNS results)) (PP (IN on) (NP (DT this) (NN task)))) (PRN (: —) (S (VP (VBG -using) (NP (NP (NP (DT the) (NN type)) (PP (IN of) (NP (DT the) (JJ side-effect)))) (CC and) (NP (NP (DT the) (JJ molecular) (NN structure)) (PP (IN of) (NP (DT the) (NNS drugs))) (ADVP (RB alone)))))) (: —)) (PP (JJ -by) (S (VP (VBG leveraging) (NP (DT a) (JJ co-attentional) (NN mechanism))))))))))) (. .))
(S (PP (IN In) (NP (JJ particular))) (, ,) (NP (PRP we)) (VP (VBP show) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG integrating) (NP (NP (JJ joint) (NN information)) (PP (IN from) (NP (DT the) (NN drug) (VBZ pairs)))) (ADVP (ADVP (RB early) (IN on)) (SBAR (WHADVP (WRB when)) (S (VP (VBG learning) (NP (NP (DT each) (NN drug) (POS 's)) (NN representation))))))))))) (. .))
